FIND A DERM    

MIRVASO

Rosacea Redness

Savings & Support

We Put MIRVASO to the Test

Facial redness of rosacea was significantly diminished in clinical studies

In clinical trials, people who used MIRVASO® (brimonidine) topical gel, 0.33%* saw their redness diminished for up to 12 hours. And for many, redness began to fade fast—often in as little as 30 minutes. As with any treatment, results can vary.

During clinical trials, 1210 participants were exposed to MIRVASO. A total of 833 participants were treated for persistent facial redness of rosacea.  330 of those were treated once daily for 29 days in vehicle-controlled trials.

These photos show actual results from the two 4‐week, phase 3, multicenter, randomized, vehicle-controlled studies evaluating the efficacy and safety of MIRVASO. Primary endpoint : Patients and researchers were asked to grade the improvement they saw at hours 3, 6, 9, and 12 following application. On day 29 of the trials, 2-grade improvement was observed with MIRVASO versus vehicle gel at hour 3 (28% vs 10%), at hour 6 (28% vs 9%), at hour 9 (22% vs 10%), and at hour 12 (22% vs 9%). Secondary endpoint: Redness was visibly reduced in as early as 30 minutes for 28% of study participants (versus 6% of people using vehicle gel).

Loading ...  

1

Study Participant #8076-001
Baseline
  • 3 Hours
  • 6 Hours
  • 12 Hours
  • 30 Minutes

2

Study Participant #8076-003
Baseline
  • 3 Hours
  • 6 Hours
  • 12 Hours
  • 30 Minutes

3

Study Participant #8139-010
Baseline
  • 3 Hours
  • 6 Hours
  • 12 Hours
  • 30 Minutes

4

Study Participant #8076-005
Baseline
  • 3 Hours
  • 6 Hours
  • 12 Hours
  • 30 Minutes

5

Study Participant #8057-024
Baseline
  • 3 Hours
  • 6 Hours
  • 12 Hours
  • 30 Minutes

Actual results with MIRVASO from 4-week clinical studies. Individual results may vary.

The safety and efficacy of MIRVASO was evaluated in 2 identical, randomized, vehicle-controlled trials with 553 patients aged 18 years and older. Study participants were randomized 1:1 to receive either MIRVASO or vehicle gel once daily for 4 weeks. The primary endpoint for both studies was 2-grade composite success at hours 3, 6, 9, and 12 on day 29. The secondary endpoint was 1-grade composite success at 30 minutes on day 1. Composite success was defined as improvement on both the Clinician Erythema Assessment and Patient Self-Assessment.

Important Safety Information
Indication:  Mirvaso® (brimonidine) topical gel, 0.33% is an alpha adrenergic agonist indicated for the topical treatment of persistent (nontransient) facial erythema of rosacea in adults 18 years of age or older.  Adverse Events:  In clinical trials, the most common adverse reactions (≥1%) included erythema, flushing, skin burning sensation and contact dermatitis.  Warnings/Precautions:  Mirvaso Gel should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension, thromboangiitis obliterans, scleroderma, or Sjögren’s syndrome. Alpha-2 adrenergic agents can lower blood pressure. Mirvaso Gel should be used with caution in patients with severe or unstable or uncontrolled cardiovascular disease. Serious adverse reactions following accidental ingestion of Mirvaso Gel by children have been reported. Keep Mirvaso Gel out of reach of children. Not for oral, ophthalmic, or intravaginal use.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

*Each gram of gel contains 5 mg of brimonidine tartrate, equivalent to 3.3 mg of brimonidine free base.

The safety and efficacy of MIRVASO was evaluated in 2 identical, randomized, vehicle-controlled trials with 553 patients aged 18 years and older. Study participants were randomized 1:1 to receive either MIRVASO or vehicle gel once daily for 4 weeks. The primary endpoint for both studies was 2-grade composite success at hours 3, 6, 9, and 12 on day 29. The secondary endpoint was 1-grade composite success at 30 minutes on day 1. Composite success was defined as improvement on both the Clinician Erythema Assessment and Patient Self-Assessment.

MIRVASO Study Description

MIRVASO was tested in 2 medical studies with 553 people aged 18 and older. Half of study participants used MIRVASO and the other half used a gel with no active ingredient for 29 days. Patients and researchers were asked to grade the improvement they saw at hours 3, 6, 9, and 12. On day 29 of the trials, 2-grade improvement was observed with MIRVASO versus inactive gel at Hour 3 (28% vs 10%), at Hour 6 (28% vs 9%), at Hour 9 (22% vs 10%), and at Hour 12 (22% vs 9%). At 30 minutes on day 1, 28% of patients using MIRVASO experienced 1-grade improvement of facial redness versus 6% for people using the inactive gel. Individual results with MIRVASO may vary.

1 of 4
Yes No
2 of 4
Yes No
3 of 4
Yes No
4 of 4
Yes No


You answered yes to questions.

Your facial redness could be related to rosacea.
To know for sure, visit your doctor and discuss your symptoms.


Your answers don't provide enough information to tell you if you could have the
facial redness of rosacea. Talk to your doctor about your symptoms.

Find a Dermatologist:
Next


Important Safety Information
Indication:  Mirvaso® (brimonidine) topical gel, 0.33% is an alpha adrenergic agonist indicated for the topical treatment of persistent (nontransient) facial erythema of rosacea in adults 18 years of age or older.  Adverse Events:  In clinical trials, the most common adverse reactions (≥1%) included erythema, flushing, skin burning sensation and contact dermatitis.  Warnings/Precautions:  Mirvaso Gel should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension, thromboangiitis obliterans, scleroderma, or Sjögren’s syndrome. Alpha-2 adrenergic agents can lower blood pressure. Mirvaso Gel should be used with caution in patients with severe or unstable or uncontrolled cardiovascular disease. Serious adverse reactions following accidental ingestion of Mirvaso Gel by children have been reported. Keep Mirvaso Gel out of reach of children. Not for oral, ophthalmic, or intravaginal use.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Continue to mirvaso.com